Rosenstock J, Bajaj HS, Janež A, et al. - Among patients not previously treated with long-term insulin therapy and whose type 2 diabetes was not adequately controlled (glycated hemoglobin level, 7.0 to 9.5%) while receiving metformin with or without a dipeptidyl peptidase 4 inhibitor, this 26-week, randomized, double-blind, double-dummy, phase 2 trial was performed to determine the efficacy as well as the safety of once-weekly insulin icodec (a basal insulin analogue) vs once-daily insulin glargine U100. The alteration in glycated hemoglobin level from baseline to week 26 was evaluated (primary endpoint). In this study with patients suffering from type 2 diabetes, once-weekly treatment with insulin icodec was shown to have glucose-lowering efficacy and a safety profile similar to those of once-daily insulin glargine U100.